Literature DB >> 24055236

Preoperative hematocrit is a powerful predictor of adverse outcomes in coronary artery bypass graft surgery: a report from the Society of Thoracic Surgeons Adult Cardiac Surgery Database.

Matthew L Williams1, Xia He, J Scott Rankin, Mark S Slaughter, James S Gammie.   

Abstract

BACKGROUND: Small series have identified a relationship between preoperative hematocrit (HCT) and outcomes in coronary artery bypass graft (CABG) surgery. The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) began collecting preoperative HCT data in 2008. In this study, analyses were performed to determine the impact of preoperative HCT on perioperative morbidity and mortality among patients undergoing isolated CABG.
METHODS: Data were collected on 182,599 patients who underwent primary isolated on-pump CABG between 2008 and 2009 and were included in the STS ACSD. Data were included only from centers that performed more than 100 on-pump cases per year during the period of study. Dialysis patients as well as those with previous cardiovascular operations or missing data for HCT were excluded. We then performed multivariable analysis using the 2008 STS CABG risk model as a guide, including HCT as a predictor. Logistic regression was performed for operative mortality and other adverse outcomes.
RESULTS: Overall operative mortality was 1.6% (3,005 of 182,599). Compared with patients with anemia (HCT <33%), patients with HCT of at least 42% had lower mortality (1.1% versus 3.4%; p < 0.0001) and lower rates of renal failure (2.0% versus 7.8%; p < 0.0001), stroke (0.9% versus 1.8%; p < 0.0001), prolonged ventilation (8.4% versus 17.5%; p < 0.0001), and deep sternal wound infection (0.3% versus 0.6%; p < 0.0001). In adjusted analyses, each 5-point decrease in preoperative HCT was associated with an 8% higher odds of death (odds ratio, 1.08; p = 0.0003), a 22% increase in the odds of postoperative renal failure (odds ratio, 1.22; p < 0.0001), and a 10% increase in the risk of deep sternal wound infection (odds ratio, 1.10; p < 0.01). Similar results were observed among patients (n = 74,292) undergoing elective CABG. The percentage of patients receiving perioperative blood transfusion decreased from 88.5% in the anemic group (HCT <33%) to 32.5% in patients with HCT of at least 42% (p < 0.0001).
CONCLUSIONS: Preoperative HCT is a powerful independent predictor of perioperative mortality as well as renal failure and deep sternal wound infection in patients undergoing isolated primary CABG operations. These findings should prompt investigation of strategies to increase preoperative HCT.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  23

Mesh:

Year:  2013        PMID: 24055236     DOI: 10.1016/j.athoracsur.2013.06.030

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Determinants of prolonged intensive care unit stay in patients after cardiac surgery: a prospective observational study.

Authors:  Theodore Kapadohos; Epameinondas Angelopoulos; Ioannis Vasileiadis; Serafeim Nanas; Anastasia Kotanidou; Andreas Karabinis; Katerina Marathias; Christina Routsi
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

Review 2.  [Diagnostics and treatment of preoperative anemia].

Authors:  C Rosenthal; C von Heymann; L Kaufner
Journal:  Anaesthesist       Date:  2019-08       Impact factor: 1.041

3.  Sex-Specific Associations Between Preoperative Anemia and Postoperative Clinical Outcomes in Patients Undergoing Cardiac Surgery.

Authors:  Juan G Ripoll; Mark M Smith; Andrew C Hanson; Phillip J Schulte; Erica R Portner; Daryl J Kor; Matthew A Warner
Journal:  Anesth Analg       Date:  2021-04-01       Impact factor: 6.627

4.  Blood transfusion practice in a referral cardiovascular center in tehran, iran: a critical point of view.

Authors:  Alireza Alizadeh-Ghavidel; Ziae Totonchi; Abedin Hoseini; Mohsen Ziyaeifard; Rasoul Azarfarin
Journal:  Res Cardiovasc Med       Date:  2014-10-14

5.  Independent association of circulating vitamin D metabolites with anemia risk in patients scheduled for cardiac surgery.

Authors:  Jana B Ernst; Tobias Becker; Joachim Kuhn; Jan F Gummert; Armin Zittermann
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

6.  Predicting the risk of death following coronary artery bypass graft made simple: a retrospective study using the American College of Surgeons National Surgical Quality Improvement Program database.

Authors:  Paul J Chung; Timothy I Carter; Joshua H Burack; Sophia Tam; Antonio Alfonso; Gainosuke Sugiyama
Journal:  J Cardiothorac Surg       Date:  2015-04-29       Impact factor: 1.637

7.  Propensity-matched analysis of association between preoperative anemia and in-hospital mortality in cardiac surgical patients undergoing valvular heart surgeries.

Authors:  Shreedhar S Joshi; Antony George; Dhananjaya Manasa; Hemalatha M R Savita; Prasad T H Krishna; A M Jagadeesh
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

Review 8.  Modifying risks to improve outcome in cardiac surgery: An anesthesiologist's perspective.

Authors:  Murali Chakravarthy
Journal:  Ann Card Anaesth       Date:  2017 Apr-Jun

9.  Benchmarking the use of blood products in cardiac surgery to stimulate awareness of transfusion behaviour : Results from a four-year longitudinal study.

Authors:  C Brouwers; B Hooftman; S Vonk; A Vonk; W Stooker; W H Te Gussinklo; R M Wesselink; C Wagner; M C de Bruijne
Journal:  Neth Heart J       Date:  2017-03       Impact factor: 2.380

Review 10.  Leukodepleted Packed Red Blood Cells Transfusion in Patients Undergoing Major Cardiovascular Surgical Procedure: Systematic Review and Meta-Analysis.

Authors:  Daniel Simancas-Racines; Ingrid Arevalo-Rodriguez; Gerard Urrutia; Diana Buitrago-Garcia; Solange Núñez-González; María José Martínez-Zapata; Eva Madrid; Xavier Bonfill; Ricardo Hidalgo-Ottolenghi
Journal:  Cardiol Res Pract       Date:  2019-02-25       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.